|
1
|
Sokka T: Work disability in early
rheumatoid arthritis. Clin Exp Rheumatol. 21(5 Suppl 31): S71–S74.
2003.PubMed/NCBI
|
|
2
|
Noss EH and Brenner MB: The role and
therapeutic implications of fibroblast-like synoviocytes in
inflammation and cartilage erosion in rheumatoid arthritis. Immunol
Rev. 223:252–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tchetverikov I, Lard LR, De Groot J,
Verzijl N, TeKoppele JM, Breedveld FC, Huizinga TW and Hanemaaijer
R: Matrix metalloproteinases-3, −8, −9 as markers of disease
activity and joint damage progression in early rheumatoid
arthritis. Ann Rheum Dis. 62:1094–1099. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tolboom TC, Van der Helm-van Mil AH,
Nelissen RG, Breedveld FC, Toes RE and Huizinga TW: Invasiveness of
fibroblast-like synoviocytes is an individual patient
characteristic associated with the rate of joint destruction in
patients with rheumatoid arthritis. Arthritis Rheum. 52:1999–2002.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunnane G, Fitzgerald O, Hummel KM,
Youssef PP, Gay RE, Gay S and Bresnihan B: Synovialtissue protease
gene expression and joint erosions in early rheumatoid arthritis.
Arthritis Rheum. 44:1744–1753. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Konttinen YT, Ainola M, Valleala H, Ma J,
Ida H, Mandelin J, Kinne RW, Santavirta S, Sorsa T, López-Otín C
and Takagi M: Analysis of 16 different matrix metalloproteinases
(MMP-1 to MMP-20) in the synovial membrane: Different profiles in
trauma and rheumatoid arthritis. Ann Rheum Dis. 58:691–697. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xue M, March L, Sambrook PN and Jackson
CJ: Differential regulation of matrix metalloproteinase 2 and
matrix metalloproteinase 9 by activated protein C: Relevance to
inflammation in rheumatoid arthritis. Arthritis Rheum.
56:2864–2874. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagase H, Visse R and Murphy G: Structure
and function of matrix metalloproteinases and TIMPs. Cardiovasc
Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van den Steen PE, Grillet B and Opdenakker
G: Gelatinase B participates in collagen II degradation and
releases glycosylated remnant epitopes in rheumatoid arthritis. Adv
Exp Med Biol. 564:45–55. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Charni-Ben Tabassi N, Desmarais S,
Bay-Jensen AC, Delaissé JM, Percival MD and Garnero P: The type II
collagen fragments Helix-II and CTX-II reveal different enzymatic
pathways of human cartilage collagen degradation. Osteoarthritis
Cartilage. 16:1183–1191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mahloogi H, Bassi DE and Klein-Szanto AJ:
Malignant conversion of non-tumorigenic murine skin keratinocytes
overexpressing PACE4. Carcinogenesis. 23:565–572. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang F, Wang L, Jiang H, Chang X and Pan
J: Inhibition of PCSK6 may play a protective role in the
development of rheumatoid arthritis. J Rheumatol. 42:161–169. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hochberg MC, Chang RW, Dwosh I, Lindsey S,
Pincus T and Wolfe F: The American college of rheumatology 1991
revised criteria for the classification of global functional status
in rheumatoid arthritis. Arthritis Rheum. 35:498–502. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartok B and Firestein GS: Fibroblast-like
synoviocytes: Key effector cells in rheumatoid arthritis. Immunol
Rev. 233:233–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Posada J and Cooper JA: Requirements for
phosphorylation of MAP kinase during meiosis in Xenopus oocytes.
Science. 255:212–215. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Walker JG and Smith MD: The Jak-STAT
pathway in rheumatoid arthritis. J Rheumatol. 32:1650–1653.
2005.PubMed/NCBI
|
|
18
|
Roman-Blas JA and Jimenez SA: NF-κB as a
potential therapeutic target in osteoarthritis and rheumatoid
arthritis. Osteoarthritis Cartilage. 14:839–848. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He
D, Ouyang G, Lin J, Shen B, Shi Y, et al: A critical role of Cyr61
in interleukin-17-dependent proliferation of fibroblast-like
synoviocytes in rheumatoid arthritis. Arthritis Rheum.
60:3602–3612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mains RE, Berard CA, Denault JB, Zhou A,
Johnson RC and Leduc R: PACE4: A subtilisin-like endoprotease with
unique properties. Biochem J. 321:587–593. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seidah NG, Chrétien M and Day R: The
family of subtilisin/kexin like pro-protein and pro-hormone
convertases: Divergent or shared functions. Biochimie. 76:197–209.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsuji A, Hashimoto E, Ikoma T, Taniguchi
T, Mori K, Nagahama M and Matsuda Y: Inactivation of proprotein
convertase, PACE4, by alpha1-antitrypsin Portland (alpha1-PDX), a
blocker of proteolytic activation of bone morphogenetic protein
during embryogenesis: Evidence that PACE4 is able to form an
SDS-stable acyl intermediate with alpha1-PDX. J Biochem.
126:591–603. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huber LC, Distler O, Tarner I, Gay RE, Gay
S and Pap T: Synovial fibroblasts: Key players in rheumatoid
arthritis. Rheumatology (Oxford). 45:669–675. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue M, McKelvey K, Shen K, Minhas N, March
L, Park SY and Jackson CJ: Endogenous MMP-9 and not MMP-2 promotes
rheumatoid synovial fibroblast survival, inflammation and cartilage
degradation. Rheumatology (Oxford). 53:2270–2279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brenner M and Gulko PS: The arthritis
severity locus Cia5a regulates the expression of inflammatory
mediators including Syk pathway genes and proteases in
pristane-induced arthritis. BMC Genomics. 13:7102012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perisic L, Hedin E, Razuvaev A, Lengquist
M, Osterholm C, Folkersen L, Gillgren P, Paulsson-Berne G, Ponten
F, Odeberg J and Hedin U: Profiling of atherosclerotic lesions by
gene and tissue microarrays reveals PCSK6 as a novel protease in
unstable carotid atherosclerosis. Arterioscler Thromb Vasc Biol.
33:2432–2443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
D'Anjou F, Routhier S, Perreault JP, Latil
A, Bonnel D, Fournier I, Salzet M and Day R: Molecular validation
of PACE4 as a target in prostate cancer. Transl Oncol. 4:157–172.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chu IM, Hengst L and Slingerland JM: The
Cdk inhibitor p27 in human cancer: Prognostic potential and
relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pagès G, Lenormand P, L'Allemain G,
Chambard JC, Meloche S and Pouysségur J: Mitogen-activated protein
kinases p42mapk and p44mapk are required for fibroblast
proliferation. Proc Natl Acad Sci USA. 90:pp. 8319–8323. 1993;
View Article : Google Scholar : PubMed/NCBI
|
